Niagen Bioscience outlines plans for 5,000-participant, 3-year Mass General Brigham trial as it targets early 2027 NR malate commercialization

Seeking Alpha · 市场快讯 · November 5, 2026 at 1:45 AM ET

Read the full report at the original publisher.